Live Feeds
● TRACKER Updated 7d ago · 32 sources tracked

Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots

Vaxcyte's stock jumped after its VAX-31 pneumococcal conjugate vaccine met every prespecified primary endpoint in the OPUS-1 pivotal Phase 3 trial, showing a safety profile comparable to Pfizer's PCV20 and Merck's PCV21. The company plans to file a Biologics License Application in the first half of 2028. The 31-valent candidate targets bacterial infectious diseases, positioning Vaxcyte as a direct challenger to established pneumococcal shots.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (32)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial and demonstrated a safety profile similar to PCV20 and PCV21, according to Vaxcyte's Q3 2026 results announcement.
  • ✓ Vaxcyte plans to submit a Biologics License Application for VAX-31 in the first half of 2028.
  • ✓ VAX-31 is a 31-valent pneumococcal conjugate vaccine designed to prevent bacterial infectious diseases.
🛡️ Source Corroboration: 32 independent reporting domains (50% confidence) ⏱ Read time: ~2 min

What changed

Positive topline data from the OPUS-1 Phase 3 trial replaced the earlier pending status, confirming VAX-31 met all prespecified primary endpoints and was well tolerated.

Live updates

  1. Vaxcyte shares rise after VAX-31 pneumococcal vaccine meets all Phase 3 endpoints

    Vaxcyte's stock jumped after its VAX-31 pneumococcal conjugate vaccine met every prespecified primary endpoint in the OPUS-1 pivotal Phase 3 trial, showing a safety profile comparable to Pfizer's PCV20 and Merck's PCV21. The company plans to file a Biologics License Application in the first half of 2028. The 31-valent candidate targets bacterial infectious diseases, positioning Vaxcyte as a direct challenger to established pneumococcal shots.

    Why it matters

    Pneumococcal vaccines from Pfizer and Merck currently dominate the market, leaving room for a broader-valence alternative. VAX-31 covers 31 serotypes, exceeding the valency of both PCV20 and PCV21. A successful BLA filing and approval could reshape adult and pediatric pneumococcal immunization and lift Vaxcyte's commercial prospects. Analyst coverage and price targets for PCVX are tracked on financial data sites, though specific targets are not provided in the source material.

    What is confirmed

    • VAX-31 met all prespecified primary endpoints in the OPUS-1 pivotal Phase 3 trial and demonstrated a safety profile similar to PCV20 and PCV21, according to Vaxcyte's Q3 2026 results announcement.
    • Vaxcyte plans to submit a Biologics License Application for VAX-31 in the first half of 2028.
    • VAX-31 is a 31-valent pneumococcal conjugate vaccine designed to prevent bacterial infectious diseases.

    Still unconfirmed

    • Vaxcyte's stock jumped following the OPUS-1 topline data, based on the feed topic and prior reporting.

    What to watch next

    • Biologics License Application submission expected in the first half of 2028
    • FDA review and potential approval of VAX-31
    • Commercial launch and uptake versus PCV20 and PCV21 if approved
    Sources used for this update (3)
    1. ca.marketscreener.com — Vaxcyte Reports Third Quarter 2026 Financial Results and ...
    2. stockanalysis.com — Vaxcyte (PCVX) Stock Forecast & Analyst Price Targets
    3. www.fool.com — Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?
    confidence 50%
  2. Vaxcyte stock jumps as VAX-31 vaccine matches Pfizer's, Merck's shots

    Vaxcyte's VAX-31 pneumococcal conjugate vaccine met all primary endpoints in its OPUS-1 Phase 3 trial, demonstrating a safety profile similar to existing vaccines PCV20 and PCV21. The company plans to submit a Biologics License Application in the first half of 2028. VAX-31 is a 31-valent vaccine designed to prevent bacterial infectious diseases. The positive topline data boosted Vaxcyte's stock.

    Why it matters

    Vaxcyte is a clinical-stage biotechnology company developing protein-based vaccines. Its leading product candidates include VAX-31 and VAX-24. The company recently reported a net loss of $297.06 million for Q3 2026. The successful trial results are a significant step towards potential FDA approval.

    What is confirmed

    • VAX-31 met all prespecified primary endpoints in the OPUS-1 Phase 3 trial.
    • VAX-31 demonstrated a safety profile similar to PCV20 and PCV21 across all ages studied.
    • Vaxcyte plans to submit a Biologics License Application for VAX-31 in the first half of 2028.
    • Vaxcyte reported a net loss of $297.06 million for Q3 2026.

    What to watch next

    • Results from OPUS-2 and OPUS-3 Phase 3 trials in the first half of 2027
    • Topline safety, tolerability and immunogenicity data from VAX-31 infant indication study by end of first half of 2027
    • FDA approval decision for VAX-31 in the first half of 2028
    Sources used for this update (4)
    1. simplywall.st — Vaxcyte Stock Gets A Lift From Strong Vaccine Trial Results
    2. finance.yahoo.com — Vaxcyte Reports Third Quarter 2026 Financial Results and ...
    3. www.panabee.com — Vaxcyte (PCVX) Q3 2026 Earnings: VAX-31 Pivotal Results and ...
    4. www.compuserve.com — Vaxcyte Reports Third Quarter 2026 Financial Results and ...
    confidence 100%
  3. Vaxcyte Stock Steady Following Positive Adult Pneumococcal Trial

    Vaxcyte shares trade at $60.81 on the NASDAQ under the ticker PCVX, supported by a market capitalization of $9.05 billion and $2.51 billion in cash reserves. The San Carlos-based clinical-stage biotechnology company develops innovative protein-based vaccines designed to prevent bacterial infectious diseases. Its leading product candidates include VAX-31, a 31-valent pneumococcal conjugate vaccine, and VAX-24, an experimental 24-valent candidate. The firm recently achieved success in its adult Phase III trials and plans to file a Biologics License Application in the first half of 2028.

    Why it matters

    The biotechnology firm utilizes a cell-free protein synthesis platform to develop vaccines that compete with established offerings from pharmaceutical giants Pfizer and Merck. Market participants monitor the company closely as it advances its pipeline of pneumococcal conjugate candidates to address invasive pneumococcal disease and pneumonia. Vaxcyte maintains a debt-to-equity ratio of 0.14 and a 52-week price range between $39.87 and $90.75.

    What is confirmed

    • Vaxcyte is a clinical-stage biotechnology company located in San Carlos, California.
    • The company trades on the NASDAQ under the ticker PCVX with a market capitalization of $9.05 billion.
    • Vaxcyte holds $2.51 billion in cash.
    • The 31-valent pneumococcal conjugate vaccine VAX-31 met every primary endpoint of its pivotal adult Phase III trial in October 2026.
    • Vaxcyte plans to submit a BLA for VAX-31 in the first half of 2028.
    • VAX-24 is an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials.

    Still unconfirmed

    • Vaxcyte's current fair value price sits at -$0.40 according to recent financial metrics.

    What to watch next

    • Submission of the Biologics License Application for VAX-31 in the first half of 2028
    • Further clinical trial developments regarding the VAX-24 candidate
    Sources used for this update (3)
    1. www.thepharmaletter.com — Vaxcyte | The Pharma Letter | The Pharmaletter
    2. markets.businessinsider.com — Vaxcyte Stock Price | PCVX Stock Quote, News, and History ...
    3. www.wallstreetzen.com — Vaxcyte Stock Price Today (NASDAQ: PCVX) Quote, Market Cap ...
    confidence 100%
  4. Vaxcyte Shares Draw Market Focus Following Pneumonia Vaccine Data

    Vaxcyte Inc continues to attract attention from stock market participants following positive late-stage trial results for its adult pneumonia vaccine candidates. Investors and analysts monitor the developer as its cell-free protein synthesis platform positions the company to rival established offerings from Pfizer and Merck. Market tracking platforms provide live pricing, charts, financial analysis, and historical performance data for the NASDAQ-listed equity under the ticker PCVX. Observers watch whether the San Carlos drugmaker can sustain its upward valuation trajectory and successfully navigate upcoming commercial milestones for its 31-valent and 24-valent candidates.

    Why it matters

    The San Carlos, California-based drugmaker develops candidates like VAX-31 and VAX-24 to prevent invasive pneumococcal disease. Analysts previously raised fair value estimates for the stock following late-stage trial results that position its lead adult pneumonia vaccine to compete against established market rivals. Market observers monitor whether the developer can maintain momentum toward commercial approvals without execution issues.

    What is confirmed

    • Vaxcyte Inc stock trades on the NASDAQ exchange under the ticker PCVX.
    • The company develops candidates including VAX-31 and VAX-24 to prevent invasive pneumococcal disease.
    • Vaxcyte is based in San Carlos, California.

    What to watch next

    • Commercial approval decisions for Vaxcyte vaccine candidates
    • Execution updates regarding the company cell-free protein synthesis platform
    • Further shifts in analyst fair value estimates and stock price performance
    Sources used for this update (2)
    1. www.livemint.com — Vaxcyte Inc Stock Live Price, Chart, Analysis, News ... - Mint
    2. www.marketbeat.com — Vaxcyte (PCVX) Stock Chart and Price History 2026 - MarketBeat
    confidence 100%
  5. Vaxcyte Stock Rises as Adult Pneumococcal Vaccine Gains Ground

    Vaxcyte shares reacted to late-stage trial results that position its lead adult pneumonia vaccine to compete against established market rivals. Analysts responded to the data by raising fair value estimates for the stock, signaling increased confidence in the company's vaccine portfolio. The San Carlos, California-based drugmaker develops candidates like the 31-valent VAX-31 and 24-valent VAX-24 to prevent invasive pneumococcal disease using a cell-free protein synthesis platform. Market observers now monitor whether the developer can maintain this momentum toward commercial approvals without facing execution issues or unexpected market share hurdles.

    Why it matters

    The company advances its pneumococcal conjugate vaccine candidates to target both infants and older adults while countering bacterial defense mechanisms. Recent late-stage outcomes have strengthened the clinical standing of Vaxcyte's adult portfolio against major pharmaceutical competitors. Analysts from multiple financial platforms have adjusted their valuations upward following the recent clinical data releases.

    What is confirmed

    • Vaxcyte is a San Carlos, California-based company advancing pneumococcal conjugate vaccine candidates including VAX-31 and VAX-24.
    • Analysts have lifted the fair value estimate for Vaxcyte stock following late-stage trial results.

    Still unconfirmed

    • Vaxcyte stock experienced a price drop during the trading day.

    What to watch next

    • Regulatory progress toward approvals and launch for Vaxcyte's late-stage vaccine programs
    • Potential execution or market-share hurdles affecting commercialization
    Sources used for this update (3)
    1. www.marketbeat.com — PCVX News Today | Why did Vaxcyte stock go down today?
    2. simplywall.st — PCVX: Adult Vaccine Leadership Looks More Attainable After A ...
    3. markets.ft.com — Vaxcyte, Inc., PCVX:NSQ summary - FT.com
    confidence 90%
  6. Vaxcyte Advances Pneumococcal Vaccine Pipeline

    San Carlos, California-based Vaxcyte is advancing its pneumococcal conjugate vaccine candidates, led by the 31-valent VAX-31 and the 24-valent VAX-24, to prevent invasive pneumococcal disease. The company utilizes a cell-free protein synthesis platform to engineer vaccines designed to overcome bacterial defense mechanisms and target high-risk groups such as infants and older adults. VAX-31 is currently advancing through an adult clinical program following positive Phase 3 OPUS-1 results and is being evaluated in infant clinical trials, while additional Phase 3 trials test concomitant administration and previous vaccination.

    Why it matters

    Invasive pneumococcal disease remains a significant global health challenge associated with high case-fatality rates, antibiotic resistance, and meningitis, particularly among vulnerable demographics. Vaxcyte develops its portfolio to offer broader coverage against bacterial infections, alongside ongoing programs targeting Group A Strep and Shigella. The company relies on advanced chemistry to build complex vaccines that deliver enhanced immunological benefits.

    What is confirmed

    • Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California.
    • VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate being studied for the prevention of invasive pneumococcal disease.
    • VAX-24 is a 24-valent pneumococcal conjugate vaccine candidate currently being evaluated in a Phase 2 infant clinical program.
    • OPUS-2 is a Phase 3 trial evaluating concomitant administration of VAX-31 with a seasonal influenza vaccine.
    • OPUS-3 is a Phase 3 trial evaluating VAX-31 in adults who have previously received pneumococcal vaccination.

    What to watch next

    • Topline data from the Phase 1 first-in-human adult study expected in the second half of 2027.
    • Further developments from the Phase 3 OPUS-2 and OPUS-3 trials for VAX-31.
    Sources used for this update (5)
    1. vaxcyte.com — Homepage - Vaxcyte
    2. vaxcyte.com — About Us - Vaxcyte
    3. finance.yahoo.com — Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - Yahoo...
    4. vaxcyte.com — Pipeline - Vaxcyte
    5. vaxcyte.com — Careers - Vaxcyte
    confidence 100%
  7. Vaxcyte Shares Surge on Positive VAX-31 Vaccine Phase 3 Results

    Vaxcyte shares surged following positive topline results from the adult Phase 3 OPUS-1 trial for its VAX-31 pneumococcal vaccine. The 31-valent vaccine met all prespecified co-primary immunogenicity endpoints, clearing strain comparisons against Pfizer's Prevnar 20 and Merck's Capvaxive while maintaining a safety profile similar to existing comparators in adults 18 and older. Alongside the clinical success, the company raised roughly US$1 billion to US$1.15 billion through concurrent common stock, pre-funded warrant, and convertible note offerings. This massive financing strengthens the biotech firm's competitive position while introducing shareholder dilution considerations.

    Why it matters

    Vaxcyte is advancing its pneumococcal vaccine pipeline through key clinical trials to challenge established market leaders. Analysts indicate that earlier Phase 1/2 data for VAX-31 established the candidate as a major competitive threat to rival shots from Pfizer and MSD. The ongoing development program positions the company for significant pipeline readouts in the coming years.

    What is confirmed

    • Vaxcyte shares surged following positive topline results from the adult Phase 3 OPUS-1 trial for its VAX-31 pneumococcal vaccine.
    • Phase 1/2 data with Vaxcyte's pneumococcal vaccine VAX-31 suggests it could be a major competitor to rival shots from Pfizer and MSD, say analysts.

    Still unconfirmed

    • The company's 2027 calendar could prove significant for its pneumococcal vaccine ambitions due to multiple clinical readouts on the horizon.

    What to watch next

    • Upcoming clinical readouts on the Vaxcyte pipeline through 2027
    • Further developments in the competitive battle between VAX-31 and rival shots from Pfizer and MSD
    Sources used for this update (2)
    1. www.rttnews.com — Show Me The Money: Vaxcyte Delivers 100%+ Gains As ...
    2. pharmaphorum.com — Vaxcyte's pneumococcal vaccine win points to Prevnar battle
    confidence 100%
  8. Vaxcyte Stock Soars Following VAX-31 Vaccine Trial Data

    Vaxcyte shares surged following positive topline results from the adult Phase 3 OPUS-1 trial for its VAX-31 pneumococcal vaccine. The 31-valent vaccine met all prespecified co-primary immunogenicity endpoints, clearing strain comparisons against Pfizer's Prevnar 20 and Merck's Capvaxive while maintaining a safety profile similar to existing comparators in adults 18 and older. Alongside the clinical success, the company raised roughly US$1 billion to US$1.15 billion through concurrent common stock, pre-funded warrant, and convertible note offerings. This massive financing strengthens the biotech firm's competitive position while introducing shareholder dilution considerations.

    Why it matters

    The clinical milestone reprices the pneumococcal vaccine market by positioning Vaxcyte to challenge established pharmaceutical competitors. Vaxcyte paired its trial success with a substantial equity and convertible debt raise to fund VAX-31 manufacturing build-out. However, the capital raise also introduces dilution questions for Nasdaq investors as the company navigates upcoming regulatory and valuation hurdles.

    What is confirmed

    • Vaxcyte reported positive topline results from the OPUS-1 adult Phase 3 trial of VAX-31, where the vaccine met all prespecified co-primary immunogenicity endpoints in adults 18 and older.
    • VAX-31 cleared every strain comparison against Pfizer's Prevnar 20 and Merck's Capvaxive.
    • Vaxcyte raised roughly US$1 billion to US$1.15 billion through concurrent common stock, pre-funded warrant, and convertible note offerings.
    • Vaxcyte's share price traded at US$66.96 following a 7-day return of 17.68% and a year-to-date gain of 44.12%.

    Still unconfirmed

    • Clinical-stage biotech volatility contributed to a 30.70% stock surge driven by Phase 2 VAX-31 data.

    What to watch next

    • Manufacturing build-out progress for VAX-31 using the newly raised capital.
    • Upcoming regulatory developments and filings for the VAX-31 pneumococcal vaccine candidate.
    Sources used for this update (10)
    1. stockstotrade.com — Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations
    2. pharmastockstoday.com — Vaxcyte Stock Jumps 30.7% After Positive VAX-31 Pneumococcal ...
    3. finance.yahoo.com — Why Vaxcyte (PCVX) Is Getting Attention Again - Yahoo Finance
    4. bullishdaily.com — Vaxcyte’s VAX-31 Success Reprices the Pneumococcal Vaccine ...
    5. www.biotechblueprint.com — Vaxcyte’s pneumococcal vaccine beats Pfizer’s and Merck’s ...
    6. simplywall.st — Vaxcyte (PCVX) Just Gave Investors Something To Think About
    7. stockanalysis.com — Vaxcyte (PCVX) Stock Price & Overview
    8. www.marketbeat.com — Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
    9. simplywall.st — Vaxcyte Stock In Focus After Phase 3 Vaccine Trial Success
    10. pharmastockstoday.com — Vaxcyte Raises $1.15 Billion to Advance VAX-31 as PCVX Shares ...
    confidence 100%
  9. Vaxcyte Stock Jumps As Pneumococcal Vaccine Matches Rivals

    Vaxcyte shares surged following positive late-stage trial results for its lead pneumococcal vaccine candidate, VAX-31. The vaccine met every primary goal in its adult Phase 3 trial named OPUS-1, demonstrating non-inferiority against established standard-of-care jabs from major pharmaceutical competitors. VAX-31 cleared a stringent bar against Pfizer's Prevnar 20 on all shared strains, while also performing strongly against Merck's Capvaxive. The successful trial data exceeded investor expectations, driving a sharp increase in the company stock value and positioning the biotech firm to challenge established players in a multibillion-dollar market.

    Why it matters

    The adult pneumococcal vaccine market represents a lucrative sector currently dominated by major pharmaceutical companies Pfizer and Merck. Vaxcyte entered this competitive space aiming to establish a new benchmark with its advanced candidate. The recent Phase 3 win provides the clinical backing necessary to challenge these established standard-of-care vaccines.

    What is confirmed

    • Vaxcyte's VAX-31 pneumococcal vaccine met every primary goal in its pivotal adult Phase 3 trial named OPUS-1.
    • Vaxcyte shares jumped following the release of the Phase 3 trial results.
    • VAX-31 was tested against Pfizer's Prevnar 20 and Merck's Capvaxive.

    Still unconfirmed

    • Vaxcyte's stock surged more than 57% in pre-market trading.
    • The adult pneumococcal vaccine market is valued at $7 billion or $8 billion.

    What to watch next

    • Further regulatory updates and filings for VAX-31
    • Additional clinical data or secondary endpoint readouts from the OPUS trial program
    Sources used for this update (14)
    1. Fierce Biotech — Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
    2. BioPharma Dive — Vaxcyte skyrockets on ‘near best-case’ pneumococcal vaccine data
    3. Investor's Business Daily — Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market
    4. Barron's — Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
    5. STAT — Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market
    6. BioSpace — Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
    7. TIKR.com — Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That “Sets a New Benchmark”
    8. contents.premium.naver.com — 📬 미국 주식 데일리 종목 분석 (2026.10.06)
    9. Yahoo Finance — NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
    10. www.biospace.com — Vaxcyte rises as pneumococcal shot establishes ‘new ...
    11. finance.yahoo.com — Vaxcyte’s stock up after pneumococcal vaccine proves non ...
    12. finance.yahoo.com — Vaxcyte Soars 36% on Phase 3 Pneumococcal Vaccine Win That ...
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community